Cargando…

SREBP1 regulates Lgals3 activation in response to cholesterol loading

Aberrant smooth muscle cell (SMC) plasticity is etiological to vascular diseases. Cholesterol induces SMC phenotypic transition featuring high LGALS3 (galectin-3) expression. This proatherogenic process is poorly understood for its molecular underpinnings, in particular, the mechanistic role of ster...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Shen, Hongtao, Owens, Gary K., Guo, Lian-Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168384/
https://www.ncbi.nlm.nih.gov/pubmed/35694209
http://dx.doi.org/10.1016/j.omtn.2022.05.028
_version_ 1784720997307383808
author Li, Jing
Shen, Hongtao
Owens, Gary K.
Guo, Lian-Wang
author_facet Li, Jing
Shen, Hongtao
Owens, Gary K.
Guo, Lian-Wang
author_sort Li, Jing
collection PubMed
description Aberrant smooth muscle cell (SMC) plasticity is etiological to vascular diseases. Cholesterol induces SMC phenotypic transition featuring high LGALS3 (galectin-3) expression. This proatherogenic process is poorly understood for its molecular underpinnings, in particular, the mechanistic role of sterol regulatory-element binding protein-1 (SREBP1), a master regulator of lipid metabolism. Herein we show that cholesterol loading stimulated SREBP1 expression in mouse, rat, and human SMCs. SREBP1 positively regulated LGALS3 expression (and vice versa), whereas Krüppel-like factor-15 (KLF15) acted as a negative regulator. Both bound to the Lgals3 promoter, yet at discrete sites, as revealed by chromatin immunoprecipitation-qPCR and electrophoretic mobility shift assays. SREBP1 and LGALS3 each abated KLF15 protein, and blocking the bromo/extraterminal domain-containing proteins (BETs) family of acetyl-histone readers abolished cholesterol-stimulated SREBP1/LGALS3 protein production. Furthermore, silencing bromodomain protein 2 (BRD2; but not other BETs) reduced SREBP1; endogenous BRD2 co-immunoprecipitated with SREBP1’s transcription-active domain, its own promoter DNA, and that of Lgals3. Thus, results identify a previously uncharacterized cholesterol-responsive dyad—SREBP1 and LGALS3, constituting a feedforward circuit that can be blocked by BETs inhibition. This study provides new insights into SMC phenotypic transition and potential interventional targets.
format Online
Article
Text
id pubmed-9168384
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-91683842022-06-10 SREBP1 regulates Lgals3 activation in response to cholesterol loading Li, Jing Shen, Hongtao Owens, Gary K. Guo, Lian-Wang Mol Ther Nucleic Acids Original Article Aberrant smooth muscle cell (SMC) plasticity is etiological to vascular diseases. Cholesterol induces SMC phenotypic transition featuring high LGALS3 (galectin-3) expression. This proatherogenic process is poorly understood for its molecular underpinnings, in particular, the mechanistic role of sterol regulatory-element binding protein-1 (SREBP1), a master regulator of lipid metabolism. Herein we show that cholesterol loading stimulated SREBP1 expression in mouse, rat, and human SMCs. SREBP1 positively regulated LGALS3 expression (and vice versa), whereas Krüppel-like factor-15 (KLF15) acted as a negative regulator. Both bound to the Lgals3 promoter, yet at discrete sites, as revealed by chromatin immunoprecipitation-qPCR and electrophoretic mobility shift assays. SREBP1 and LGALS3 each abated KLF15 protein, and blocking the bromo/extraterminal domain-containing proteins (BETs) family of acetyl-histone readers abolished cholesterol-stimulated SREBP1/LGALS3 protein production. Furthermore, silencing bromodomain protein 2 (BRD2; but not other BETs) reduced SREBP1; endogenous BRD2 co-immunoprecipitated with SREBP1’s transcription-active domain, its own promoter DNA, and that of Lgals3. Thus, results identify a previously uncharacterized cholesterol-responsive dyad—SREBP1 and LGALS3, constituting a feedforward circuit that can be blocked by BETs inhibition. This study provides new insights into SMC phenotypic transition and potential interventional targets. American Society of Gene & Cell Therapy 2022-05-18 /pmc/articles/PMC9168384/ /pubmed/35694209 http://dx.doi.org/10.1016/j.omtn.2022.05.028 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Li, Jing
Shen, Hongtao
Owens, Gary K.
Guo, Lian-Wang
SREBP1 regulates Lgals3 activation in response to cholesterol loading
title SREBP1 regulates Lgals3 activation in response to cholesterol loading
title_full SREBP1 regulates Lgals3 activation in response to cholesterol loading
title_fullStr SREBP1 regulates Lgals3 activation in response to cholesterol loading
title_full_unstemmed SREBP1 regulates Lgals3 activation in response to cholesterol loading
title_short SREBP1 regulates Lgals3 activation in response to cholesterol loading
title_sort srebp1 regulates lgals3 activation in response to cholesterol loading
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168384/
https://www.ncbi.nlm.nih.gov/pubmed/35694209
http://dx.doi.org/10.1016/j.omtn.2022.05.028
work_keys_str_mv AT lijing srebp1regulateslgals3activationinresponsetocholesterolloading
AT shenhongtao srebp1regulateslgals3activationinresponsetocholesterolloading
AT owensgaryk srebp1regulateslgals3activationinresponsetocholesterolloading
AT guolianwang srebp1regulateslgals3activationinresponsetocholesterolloading